Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL30P11 (Ribosomal protein L30 pseudogene 11) is classified as a pseudogene and does not encode a functional protein. It is related to the functional RPL30 gene, which encodes a component of the 60S ribosomal subunit involved in protein synthesis[5][6][1]. Unlike the parent gene, RPL30P11 is considered a processed pseudogene and lacks coding potential or documented biological function. There is no evidence supporting its role as a therapeutic target, and it is not associated with any drugs, mechanisms of action, or clinical biomarkers. Such pseudogenes often arise through retrotransposon-mediated gene duplication events and typically do not contribute to normal cellular function or disease[8][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L30 pseudogene 11 (RPL30P11).